Major Talent Acquisition in the Obesity Biotech Industry

Structure Therapeutics (GPCR) has appointed Matthew Lang as Chief Operating Officer (COO) and General Counsel (GC). Matthew Lang was a key figure in designing the mega‑deal in which Pfizer (PFE) will acquire Metsera for a total of $10 billion in November 2025. This appointment reflects more than a single executive move; it signals the company’s intent to launch global commercialization and strategic partnership efforts for its oral GLP‑1 receptor agonist candidate aleniglipron. With the global obesity market projected to reach up to $150 billion by 2030, Structure is securing leadership with extensive large‑deal experience to actively compete for market leadership.

Successful Phase 2 Results for aleniglipron and Entry into Phase 3

Structure’s lead pipeline candidate aleniglipron recently completed the Phase 2b ACCESS‑II trial, demonstrating a 16.3 % greater weight loss versus placebo in the 180 mg dose group. This injectable‑like efficacy underscores the strong competitive advantage of an oral therapy with high convenience. Based on these data, the company plans to enter a global Phase 3 clinical program by Q3 2026. In designing the Phase 3 trial and coordinating with regulatory authorities worldwide, Lang’s contract‑management expertise—honed while overseeing Metsera’s M&A and strategy—will be a decisive asset.

Pfizer’s Metsera Acquisition and Its Impact on the Obesity Market

Pfizer’s acquisition of Metsera, led by Matthew Lang, was a landmark transaction that reshaped the global obesity market. After discontinuing development of its own oral GLP‑1 candidate danuglipron, Pfizer acquired Metsera for $10 billion (including $7 billion upfront and $3 billion in contingent value rights) as the premier pathway to market entry. Metsera’s flagship pipeline includes the once‑monthly injectable GLP‑1 receptor agonist berobenatide (formerly MET‑097i), which is progressing smoothly from Phase 2b toward Phase 3. The deal exemplifies the M&A trend whereby large pharma companies offset internal development setbacks by acquiring external pipelines.

Intense Competition in the Oral Obesity‑Treatment Market

The global obesity‑treatment market is currently dominated by Eli Lilly (LLY) and Novo Nordisk (NVO), both rapidly advancing oral pipeline candidates. Eli Lilly is conducting a Phase 3 trial of the oral obesity drug orforglipron, while Novo Nordisk is heavily investing in oral semaglutide and amycretin programs. In this competitive landscape, Viking Therapeutics (VKTX) is pursuing its VK2735 candidate, and Structure’s aleniglipron must carve out a distinct niche as an oral small‑molecule therapy. Hiring Matthew Lang positions Structure to maximize negotiating leverage in future license‑out deals or strategic co‑development partnerships with global big‑pharma partners.